" class="no-js "lang="en-US"> Raumedic on "Components for the Pharmaceutical Industries"
Thursday, March 23, 2023

Breaking News

OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Medtronic to Boost AI Innovation with New Platform Introduction Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

March 10 2023

Lena Wagner & Simone Marquardt, Raumedic, on Components for the Pharmaceutical and MedTech Industries

In this video, Lena Wagner and Simone Marquardt from Raumedic discuss the components that the company offers for the pharmaceutical and medtech industries.

They showcase how Raumedic’s products are designed to meet the high standards required in these industries. They also emphasize the importance of customization and how Raumedic works closely with their clients to create tailored solutions for their specific needs.

Additionally, Lena and Simone explain why they are regular visitors to Pharmapack events. They see it as an opportunity to connect with other companies and individuals in the industry, learn about the latest trends and innovations, and showcase their own products and expertise.

  1. OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia

    Diseases

     Read more
  2. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

    News

     Read more
  3. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

    Diseases

     Read more
  4. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

    Drug Development

     Read more
  5. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

    News

     Read more
More On